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BACKGROUND Management of small coronary vessel disease with
percutaneous coronary interventions is often associated with high
recurrences and an increased risk of late or very late adverse events,
including stent thrombosis. Currently, little is known about bio-
vascular scaffold (BVS) behavior in this setting.
METHODS A retrospective cohort analysis was performed in consec-
utive patients treated with BVS implantation in vessels whose diam-
eter was <2.8mm at 3 high volume Italian centers with a certiﬁcated
experience of >2.5 years of BVS implantation. Primary end-point was
the occurrence of BVS failure (a composite of target lesion revascu-
larization, TLR, and BVS deﬁnite thrombosis) at the longest available
follow up.
RESULTS A total of 121 patients (133 lesions) were treated between
March 2013-December 2014. Baseline clinical and angiographic char-
acteristics, that describe a highly complex patient population, are
described in Table. Procedural success was obtained in all patients. In-
hospital events included 2 perforations (1.5%) both sealed with
covered stents. At the longest available clinical follow up (average
126 months), 70% of patients were still on dual antiplatelet treat-
ment. Angiographic follow-up was performed in 10% of patients.
Eleven patients (8.2%) suffered a BVS failure, including 11 (8.2%) TLR
and 2 (1.6%) scaffold thrombosis. We also registered 2 (1.6%) deaths
(one cardiac) and 2 (1.6%) target-vessel myocardial infarctions.
Table. Clinical, Angiographic and Procedural characteristics.Patients, n 121Lesions treated, n 133 In-stent restenosis, % 19.4Age, years 61.78.8 Thrombus-containing
lesions, %17.9Males, % 82.3 Average vessel
diameter, mmSD
2.470.14Diabetes Mellitus, % 30.6 Percent diameter
stenosis, %SD
79.511.8Hypertension, % 70.0 Predilatation, % 96.3History of smoke, % 28.4 Predilatation balloon
diameter, mmSD
2.50.34LVEF, %SD 53.27.2 Biovascular scaffold
diameter, mmSD2.630.23Clinical Presentation Biovascular scaffold
length(s), mmSD
32.914.2Stable coronary
artery disease,
%66.2 Biovascular scaffold
underexpansion, %3.8NSTEMI, % 22.0 Postdilatation, % 94.8STEMI, % 21.8 Postdilatation balloon
size, mmSD
2.80.19Type B2/C lesions, % 70.7 Intravascular imaging
guidance, %11.1CONCLUSIONS To the best of our knowledge, this is the largest reg-
istry of small coronary vessels treated with BVS. In this cohort of
consecutive patients, BVS implantation was technically feasible and
effective in maintaining vessel patency after 12 months.
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BACKGROUND Treatment of in-stent restenosis (ISR) is still chal-
lenging for interventional cardiologists. In this contest the use of
bioresorbable vascular scaffold (BVS) appears very attractive as it al-
lows drug delivery combined with transient vessel scaffolding thus
obviating the limitations of drug-eluting stent or balloon as ISR
therapy. Aim of this multicenter registry was to investigate the
feasibility of BVS use in ISR lesions.
METHODS A prospective analysis was performed on all patients that
underwent percutaneous coronary intervention (PCI) with BVS im-
plantation for ISR at 7 Italian Centers. Primary endpoints were pro-
cedural success deﬁned as the successful delivery and deployment of
the BVS at the target lesion with less than 30% ﬁnal residual stenosis
without in-hospital major adverse cardiac and/or cerebro-vascular
events (MACCE) deﬁned as a composite of cardiac death, Q-wave
myocardial infarction, stroke, or any repeat target lesion revasculari-
zation (surgical or percutaneous).
RESULTS From April 2012 to June 2014, a total of 113 patients (124
lesions) underwent PCI for ISR with BVS implantation at the partici-
pating Centers. Among the ISR lesions, the majority were DES-ISR (74,
59.7%); 35 (28.2%) recurrent-ISR and according to the angiographic
pattern 79 (63.7%) were deﬁned as diffuse-ISR. The mean patient age
was 65.910 years and 105 patients (84.7%) were male. Type 2 dia-
betes mellitus was present in 35 (28%) patients while chronic kidney
disease in 19 (15.3%). PCI procedures were performed in 71 (57.3%)
patients presenting with stable CAD, 46 (37.1%) with UA/NSTEMI and
7 (5.6%) with STEMI. Intracoronary imaging evaluation was performed
in 26 (21%) lesions before and in 30 (24.2%) lesions post-BVS im-
plantation. Target lesion length was 28.0615 mm requiring the use of
1.40.6 BVS per lesion, with a mean BVS length of 34.818.4 mm per
lesion. Lesion pre dilatation was mandatory, and post dilatation was
needed in 87.9% of cases. Procedural success was achieved in 123
(99.2%) patients. In one patient a bailout DES implantation was
needed because of proximal BVS edge dissection occurrence not
suitable for a second BVS implantation. No in-hospital and 30-day
MACCE occurred. At median follow-up time of 17 months (IQR 12-23)
MACCE rate was 12.1%. TLR per patient was 7.1%, TLR per lesion 6.5%,
while cardiac death 2.4%. Deﬁnite BVS-in-stent thrombosis was re-
ported in 1 patient (0.8%).
CONCLUSIONS To the best of our knowledge, we report the largest
registry of complex ISR lesions treated with BVS. The results of our
registry suggest that BVS implantation for the treatment of ISR is
technically feasible and associated with favorable mid-term clinical
outcomes. These data could be considered hypothesis generating for a
future randomized clinical trial.
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BACKGROUND Everolimus eluting ABSORB(tm) bioresorbable
vascular scaffold (BVS) represents a novel approach for PCI with
transient vessel support and drug delivery without the long term
limitations of metallic DES. Diabetic patients tend to have a worse
